You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 19, 2024

Abbvie Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Abbvie
International Patents:2727
US Patents:229
Tradenames:124
Ingredients:99
NDAs:138
Drug Master File Entries: 1
Patent Litigation for Abbvie: See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No RE43879 ⤷  Try a Trial ⤷  Try a Trial
Abbvie RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-003 Mar 16, 2022 RX Yes Yes 11,680,069 ⤷  Try a Trial Y Y ⤷  Try a Trial
Abbvie ACUVAIL ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 022427-001 Jul 22, 2009 RX Yes Yes 8,512,717 ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie KYBELLA deoxycholic acid SOLUTION;SUBCUTANEOUS 206333-001 Apr 29, 2015 AP RX Yes Yes 9,522,155 ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No 11,590,128 ⤷  Try a Trial ⤷  Try a Trial
Abbvie CHOLOXIN dextrothyroxine sodium TABLET;ORAL 012302-005 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 019732-001 Jan 26, 1989 4,954,298 ⤷  Try a Trial
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-002 Sep 25, 1986 6,274,169*PED ⤷  Try a Trial
Abbvie BIAXIN XL clarithromycin TABLET, EXTENDED RELEASE;ORAL 050775-001 Mar 3, 2000 6,010,718 ⤷  Try a Trial
Abbvie NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-002 Jun 21, 2010 5,061,703*PED ⤷  Try a Trial
Abbvie MAVIK trandolapril TABLET;ORAL 020528-001 Apr 26, 1996 4,233,361 ⤷  Try a Trial
Abbvie ENABLEX darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 021513-001 Dec 22, 2004 6,106,864 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-06-10
➤ Subscribe Delayed-release Tablets 800 mg ➤ Subscribe 2011-07-13
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablets 7.5 mg and 15 mg ➤ Subscribe 2008-12-22
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Delayed-release Capsules 400 mg ➤ Subscribe 2014-06-17
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-08-16
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 2013-06-17
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 2013-06-12
➤ Subscribe Injection 10 mg/mL (2 mL) ➤ Subscribe 2018-07-13
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12

Supplementary Protection Certificates for Abbvie Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1713823 1490064-1 Sweden ⤷  Try a Trial PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
2435432 C201730016 Spain ⤷  Try a Trial PRODUCT NAME: VENETOCLAX; NATIONAL AUTHORISATION NUMBER: EU/1/16/1138; DATE OF AUTHORISATION: 20161205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1138; DATE OF FIRST AUTHORISATION IN EEA: 20161205
2049079 LUC00006 Luxembourg ⤷  Try a Trial PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323
2692346 CR 2017 00049 Denmark ⤷  Try a Trial PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
0503785 CA 2011 00026 Denmark ⤷  Try a Trial PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2435432 1790021-8 Sweden ⤷  Try a Trial PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138 20161207
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.